The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of multifaceted antibodies the company believes to be advances over existing ...
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.
Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead ...
As part of a larger review, analyst Leonid Timashev identified 13 companies that could see deal interest as well as more than ...
The ruling, related to a lawsuit from several major medical organizations, stated that HHS ignored established protocols in altering the childhood immunization schedule and overhauling a key CDC panel ...
The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat ...
The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement ...
Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company ...
The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, ...
More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor ...
Xenon shares skyrocketed nearly 50% on results that handily beat Wall Street expectations. Elsewhere, Capricor got a decision date for a spurned cell therapy and AbbVie and Regeneron showcased obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results